| 3.13 0.08 (2.62%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.84  |
1-year : | 4.12 |
| Resists | First : | 3.28 |
Second : | 3.52 |
| Pivot price | 3.06 |
|||
| Supports | First : | 2.9 | Second : | 2.41 |
| MAs | MA(5) : | 3.01 |
MA(20) : | 3.06 |
| MA(100) : | 3.67 |
MA(250) : | 5.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 24.1 |
D(3) : | 14.5 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 9.2 | Low : | 2.9 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NTRB ] has closed below upper band by 29.3%. Bollinger Bands are 50.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.15 - 3.17 | 3.17 - 3.18 |
| Low: | 2.97 - 2.98 | 2.98 - 3 |
| Close: | 3.11 - 3.13 | 3.13 - 3.15 |
Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.
Mon, 13 Jul 2026
Nutriband Inc. (NTRB) Slips 2.33% as Stock Tests Key Support at $2.79 - Sweep Order Flow - dars.gov.et
Mon, 22 Jun 2026
NutriBand Secures Amended Three-Year $5 Million Credit Line at 7% to Support AVERSA - TradingView
Mon, 22 Jun 2026
[8-K] NutriBand Inc. Reports Material Event | NTRB 8-K Filing - Stock Titan
Thu, 18 Jun 2026
Nutriband Inc (NTRB) Institutional Confidence - TradingKey
Tue, 09 Jun 2026
Nutriband Inc. (NTRB) Slips Modestly as Stock Tests Key Support Levels - Rating Change - DonanımHaber
Mon, 30 Mar 2026
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 56.8 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 153 (K) |
| Shares Short P.Month | 172 (K) |
| EPS | -2.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.49 |
| Profit Margin | 0 % |
| Operating Margin | -289.5 % |
| Return on Assets (ttm) | -78.2 % |
| Return on Equity (ttm) | -145.8 % |
| Qtrly Rev. Growth | -35.1 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -0.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.28 |
| PEG Ratio | 0 |
| Price to Book value | 6.38 |
| Price to Sales | 21.14 |
| Price to Cash Flow | -8.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|